Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  British medical journal

• Publication date

  1986-01-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/bmj.292.6512.16PMID 3080047PMCID PMC1338971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

  1986cited by this paper
• Effects of cyclosporin on prednisolone metabolism.

  1984cited by this paper
• The effect of renal transplantation with a minimal steroid regime on uraemic hypertriglyceridaemia.

  1984cited by this paper
• Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporin.

  1983cited by this paper
• Lipid abnormalities in uremia, dialysis, and transplantation.

  1981cited by this paper
• Cyclosporin.

  1980cited by this paper

• A Review of the Pharmacokinetics of Cyclosporin

  2022cites this paper
• Coronary Atherosclerosis

  2020cites this paper
• circulation of bile salts in health and disease

  2017cites this paper
• selective activation of SREBP-2 Cyclosporin-induced dyslipoproteinemia is associated with

  2016cites this paper
• Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function.

  2014cites this paper
• Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant Recipients

  2012cites this paper
• The effect of cyclosporin A on rat pancreatic B-cell: interaction with the calcium-antagonist diltiazem.

  2009cites this paper
• Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors.

  2009cites this paper
• Primary care of the renal transplant patient

  2007cites this paper
• Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk

  2006cites this paper
• Statins and solid organ transplantation.

  2006cites this paper
• Comment Investigation of Heart Transplant Coronary Atherosclerosis

  2005cites this paper
• Hypertriglyceridemia: Apheretic Treatment

  2005cites this paper
• The enterohepatic circulation of bile salts in health and disease : a kinetic approach

  2004cites this paper
• Cyclosporine A–Induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation

  2004cites this paper
• Cyclosporin A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation

  2004cites this paper
• Apolipoprotein C‐III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation

  2002cites this paper
• Nutritional and metabolic support in patients undergoing bone marrow transplantation.

  2002cites this paper
• Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients

  2001cites this paper
• Einfluss der Immunsuppression auf kardiovaskuläre Risikofaktoren nach Nierentransplantation

  2001cites this paper
• Pediatric renal transplantation.

  2001cites this paper
• PRODUCT MONOGRAPH

  2000cites this paper
• Dyslipidemia in Rheumatic Disorders

  2000cites this paper
• Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2.

  1999cites this paper
• Serum paraoxonase activity changes in uremic and kidney-transplanted patients.

  1999cites this paper
• [Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment].

  1999cites this paper
• Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience

  1999cites this paper
• Serum Paraoxonase Activity Changes in Uremic and Kidney-Transplanted Patients

  1999cites this paper
• Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2.

  1999cites this paper
• Effect of probucol on hypercholesterolemia in renal transplant patients.

  1999cites this paper
• Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients.

  1999cites this paper
• The effect of cyclosporin A on plasma lipids during the first year after renal transplantation.

  1999cites this paper
• Lipoprotein abnormalities in long‐term stable liver and renal transplanted patients. A comparative study

  1998cites this paper
• Lipoprotein changes in children after liver transplantation: Mild hypertriglyceridemia and a decrease in HDL/HDL ratio

  1998cites this paper
• Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus.

  1998cites this paper
• Lipid abnormalities in stable liver transplant recipients – effects of cyclosporin, tacrolimus, and steroids

  1998cites this paper
• The role of lipids in transplant vascular disease.

  1998cites this paper
• Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation.

  1998cites this paper
• Obesity and Hypercholesterolemia following Heart Transplantation

  1998cites this paper
• Obesity and hypercholesterolemia following heart transplantation.

  1998cites this paper
• The interaction of modified low density lipoproteins with glomerular mesangial cells and its potential influence on glomerulosclerosis

  1998cites this paper
• Hyperlipidemia in liver transplant recipients: prevalence and risk factors.

  1997cites this paper
• Use of HMG-CoA Reductase Inhibitors after Kidney and Heart Transplantation

  1997cites this paper
• HMG-CoA reductase inhibitors in organ transplantation.

  1997cites this paper
• Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.

  1997cites this paper
• Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.

  1997cites this paper
• The risk of coronary artery disease after heart transplantation is increased in patients receiving low‐dose cyclosporine, regardless of blood cyclosporine levels

  1997cites this paper
• Lipoprotein pattern in end‐stage renal disease and following successful renal transplantation

  1997cites this paper
• Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients.

  1997cites this paper
• Clinically Significant Drug Interactions with Cyclosporin An Update

  1996cites this paper
• Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.

  1996cites this paper
• Risk Factors for Premature Coronary Heart Disease after Successful Liver Transplantation in Adults

  1996cites this paper
• Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.

  1996cites this paper
• Impact of pancreas transplantation on diabetic secondary complications and quality of life

  1996cites this paper
• Lipoprotein metabolism in renal replacement therapy: a review.

  1996cites this paper
• Dyslipidemia in renal disease.

  1996cites this paper
• Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients

  1996cites this paper
• Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

  1995cites this paper
• Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension.

  1995cites this paper
• Metabolic Abnormalities Following Heart Transplantation in Patients with Idiopathic Cardiomyopathy

  1995cites this paper
• Renal transplantation and dyslipidemia: characterization of a population and treatment with diet and low dose lovastatin.

  1995cites this paper
• Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation.

  1995cites this paper
• Lipoprotein profile after combined kidneypancreas transplantation in insulindependent diabetes mellitus

  1995cites this paper
• Post‐transplant hyperlipidemia: Risk factors and response to dietary modification and gemfibrozil therapy

  1995cites this paper
• The effect of cyclosporine and methylprednisolone on plasma lipoprotein levels in rats.

  1995cites this paper
• Approaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant Recipient

  1995cites this paper
• The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.

  1995cites this paper
• Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.

  1995cites this paper
• Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.

  1995cites this paper
• Effects of Immunosuppressive Agents on Glucose Metabolism

  1995cites this paper
• Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy.

  1995cites this paper
• Hyperlipidemia in renal transplant recipients: does it matter and can we treat it?

  1995cites this paper
• Lipoprotein profile after combined kidney-pancreas transplantation in insulin-dependent diabetes mellitus

  1995influential citation
• Hiperlipidemia en el trasplante renal. Tratamiento con pantetina

  1995cites this paper
• Metabolic risk factors for atherosclerosis in heart transplant recipients.

  1994cites this paper
• CYCLOSPORINE IN DERMATOLOGY: PHARMACOLOGY AND CLINICAL USE

  1994cites this paper
• Low dosage of cyclosporine and increased occurrence of chronic rejection in heart-transplanted patients.

  1994cites this paper
• Hyperlipidemia and glucose intolerance in the post-renal transplant patient.

  1994cites this paper
• LOW CHOLESTEROL AND IMPAIRED CARDIAC FUNCTION FOLLOWING HEART TRANSPLANTATION

  1994cites this paper
• Metabolic factors and outcome of organ transplantation.

  1994cites this paper
• Hyperlipidemia in Renal Transplant Recipients: Natural History and Response to Treatment

  1994cites this paper
• Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506.

  1994cites this paper
• Lipid profile in renal transplant recipients under various immunosuppressive regimens.

  1994cites this paper
• Relation of cyclosporine blood levels to adverse effects on lipoproteins.

  1994cites this paper
• Possible role of brown adipose tissue as a mediator during cyclosporine-A treatment.

  1994cites this paper
• THE EFFECT OF FK506 VERSUS CYCLOSPORINE ON GLUCOSE AND LIPID METABOLISM—A RANDOMIZED TRIAL

  1994cites this paper
• Interaction between probucol and cyclosporine in renal transplant patients.

  1994cites this paper
• Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2.

  1994cites this paper
• Hyperlipidemia in stable renal transplant recipients.

  1994cites this paper
• Different trends in immunosuppression: 10 years' experience with cyclosporine after living related donor renal transplantation.

  1994cites this paper
• Role of clinical pharmacy specialist in nutrition management of bone marrow transplant patient.

  1993cites this paper
• THE BENEFICIAL EFFECTS OF STEROID WITHDRAWAL ON BLOOD PRESSURE AND LIPID PROFILE IN CHILDREN POSTTRANSPLANTATION IN THE CYCLOSPORINE ERA

  1993cites this paper
• LONG‐TERM CONSEQUENCES OF DIFFERENT IMMUNOSUPPRESSIVE REGIMENS FOR RENAL ALLOGRAFTS

  1993cites this paper
• In situ localization and distribution pattern of apolipoproteins in arterial walls: a comparative study in atherosclerosis and renal transplant arteriopathy.

  1993cites this paper
• Impact of time-interval after transplantation and therapy with fibrates on serum cholesterol levels in renal transplant patients.

  1993cites this paper
• A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine.

  1993cites this paper
• Managing nutrition problems in transplant patients.

  1993cites this paper
• Low-density lipoprotein metabolism in rats treated with cyclosporine.

  1993cites this paper
• Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile

  1993cites this paper
• Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy.

  1993cites this paper